SEC Form 4 · accession 0001225208-19-004612

PFIZER INC · PFE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President R&D

Period of report

Mar 1, 2019

Accepted (ET)

Mar 5, 2019 · 4:54 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000078003

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Mar 1, 2019	M	57,609	$30.59	A	390,097	D
Common Stock^F2	Mar 1, 2019	M	48,582	$32.23	A	438,679	D
Common Stock	Mar 1, 2019	S	2,300	$43.59	D	436,379	D
Common Stock	Mar 1, 2019	S	5,927	$43.58	D	430,452	D
Common Stock	Mar 1, 2019	S	14,760	$43.57	D	415,692	D
Common Stock	Mar 1, 2019	S	77,484	$43.56	D	338,208	D
Common Stock	Mar 4, 2019	S	2,187	$43.56	D	336,021	D
Common Stock	Mar 4, 2019	S	2,400	$43.55	D	333,621	D
Common Stock	Mar 4, 2019	S	2,600	$43.54	D	331,021	D
Common Stock	Mar 4, 2019	S	3,250	$43.53	D	327,771	D
Common Stock	Mar 4, 2019	S	38,645	$43.52	D	289,126	D
Common Stock	holding	—	—		—	1,625	I	By Rule 16b-3 Plan

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Appreciation Rights	$30.59	Mar 1, 2019	M	155,172	D	Feb 25, 2019	Feb 25, 2021	Common Stock	155,172	0	D
Stock Appreciation Rights	$32.23	Mar 1, 2019	M	126,366	D	Jun 16, 2018	Feb 27, 2021	Common Stock	126,366	0	D

F1Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price of $42.45)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.
F2Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price of $42.45)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.